About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Cyp3a13tm1Nki
targeted mutation 1, The Netherlands Cancer Institute
MGI:3764486
Summary 4 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Cyp3a13tm1Nki/Cyp3a13tm1Nki involves: 129P2/OlaHsd * FVB MGI:3775618
cx2
Cyp3a13tm1Nki/Cyp3a13tm1Nki
Del(5Cyp3a57-Cyp3a59)2Nki/Del(5Cyp3a57-Cyp3a59)2Nki
involves: 129P2/OlaHsd * FVB/N MGI:3775621
cx3
Cyp3a13tm1Nki/Cyp3a13tm1Nki
Del(5Cyp3a57-Cyp3a59)2Nki/Del(5Cyp3a57-Cyp3a59)2Nki
Tg(Vil1-CYP3A4)1Nki/0
involves: 129P2/OlaHsd * FVB/N MGI:3775625
cx4
Cyp3a13tm1Nki/Cyp3a13tm1Nki
Del(5Cyp3a57-Cyp3a59)2Nki/Del(5Cyp3a57-Cyp3a59)2Nki
Tg(APOE-CYP3A4)A1Nki/0
involves: 129P2/OlaHsd * FVB/N MGI:3775628


Genotype
MGI:3775618
hm1
Allelic
Composition
Cyp3a13tm1Nki/Cyp3a13tm1Nki
Genetic
Background
involves: 129P2/OlaHsd * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cyp3a13tm1Nki mutation (4 available); any Cyp3a13 mutation (39 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
normal phenotype
• hematological, plasma clinical chemistry and pathological examination reveal no abnormalities




Genotype
MGI:3775621
cx2
Allelic
Composition
Cyp3a13tm1Nki/Cyp3a13tm1Nki
Del(5Cyp3a57-Cyp3a59)2Nki/Del(5Cyp3a57-Cyp3a59)2Nki
Genetic
Background
involves: 129P2/OlaHsd * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cyp3a13tm1Nki mutation (4 available); any Cyp3a13 mutation (39 available)
Del(5Cyp3a57-Cyp3a59)2Nki mutation (0 available); any Del(5Cyp3a57-Cyp3a59)2Nki mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• administration of 10 mg/kg docetaxel results in death by euthanasia at day 6 and 7 whereas wild-type mice recover to normal weight without lethality by day 25

homeostasis/metabolism
• administration of 10 mg/kg docetaxel results in death by euthanasia at day 6 and 7 whereas wild-type mice recover to normal weight without lethality by day 25
• administration of 10 mg/kg docetaxel results in greater weight loss than in wild-type mice and death by euthanasia at day 6 and 7 whereas wild-type mice recover to normal weight without lethality by day 25
• docetaxel M-2 metabolites are not detected in microsomes unlike in wild-type microsomes treated with docetaxel
• the area under the plasma docetaxel concentration versus time curve is 6.8-fold higher than in wild-type mice
• the oral bioavailability of docetaxel is 52% compared to 8.1% in wild-type mice
• docetaxel levels are 7-fold higher in the liver and 5-fold higher in the small intestine compared to in wild-type mice
• clearance of docetaxel is reduced compared to in wild-type mice
• metabolite formation is reduced 24-fold compared to in wild-type mice




Genotype
MGI:3775625
cx3
Allelic
Composition
Cyp3a13tm1Nki/Cyp3a13tm1Nki
Del(5Cyp3a57-Cyp3a59)2Nki/Del(5Cyp3a57-Cyp3a59)2Nki
Tg(Vil1-CYP3A4)1Nki/0
Genetic
Background
involves: 129P2/OlaHsd * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cyp3a13tm1Nki mutation (4 available); any Cyp3a13 mutation (39 available)
Del(5Cyp3a57-Cyp3a59)2Nki mutation (0 available); any Del(5Cyp3a57-Cyp3a59)2Nki mutation (0 available)
Tg(Vil1-CYP3A4)1Nki mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• docetaxel M-2 metabolites are not detected in hepatic microsomes unlike in wild-type microsomes treated with docetaxel
• however, M-2 metabolites are detected in intestinal microsomes
• docetaxel accumulation in the small intestines is decreased 4-fold compared to in Del(15Cyp3a57-Cyp3a59)1Ahs Cyp3a13tm1Ahs homozygotes following intravenous injection of docetaxel
• however, upon oral administration of docetaxel plasma levels are reduced 16.6 fold compared to in Del(15Cyp3a57-Cyp3a59)1Ahs Cyp3a13tm1Ahs homozygotes
• oral bioavailability is decreased to 1.8% compared to 8.1% in wild-type mice
• clearance of docetaxel is reduced compared to in wild-type mice




Genotype
MGI:3775628
cx4
Allelic
Composition
Cyp3a13tm1Nki/Cyp3a13tm1Nki
Del(5Cyp3a57-Cyp3a59)2Nki/Del(5Cyp3a57-Cyp3a59)2Nki
Tg(APOE-CYP3A4)A1Nki/0
Genetic
Background
involves: 129P2/OlaHsd * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cyp3a13tm1Nki mutation (4 available); any Cyp3a13 mutation (39 available)
Del(5Cyp3a57-Cyp3a59)2Nki mutation (0 available); any Del(5Cyp3a57-Cyp3a59)2Nki mutation (0 available)
Tg(APOE-CYP3A4)A1Nki mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• docetaxel M-2 metabolites are not detected in intestinal microsomes unlike in wild-type microsomes treated with docetaxel
• plasma docetaxel are higher than in wild-type mice following intravenous administration
• oral administration of docetaxel results in a 2.2-fold reduction of plasma levels compared to in Del(15Cyp3a57-Cyp3a59)1Ahs Cyp3a13tm1Ahs homozygotes
• however, M-2 metabolites are detected in hepatic microsomes
• docetaxel accumulation in the liver is decreased 19-fold compared to in Del(15Cyp3a57-Cyp3a59)1Ahs Cyp3a13tm1Ahs homozygotes
• however, plasma docetaxel levels following intravenous injection are decreased 5.5-fold compared to in Del(15Cyp3a57-Cyp3a59)1Ahs Cyp3a13tm1Ahs homozygotes to near normal levels and mice exhibit near normal clearance of docetaxel
• oral bioavailability is increased to 21% compared to 8.1% in wild-type mice





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/19/2024
MGI 6.24
The Jackson Laboratory